Evidence-based medicine is an important initiative of the U.S. National Institutes of Health. However, published data are limited. Medical knowledge can be advanced through pharmacoepidemiology and data mining research of very large databases, data warehouses. Before Vioxx™ (rofecoxib) and Celebrex™ (celecoxib) were publicly suspected of being associated with acute myocardial infarction and stroke, etodolac was evaluated for gastrointestinal safety using a data warehouse constructed from several data sources and data mining tools embedded with pharmacoepidemiologic methods. Results were published in a top tier medical journal, and established gastrointestinal safety of a generic COX-2 analgesic medication. This project demonstrates that the knowledge needed for evidence-based medicine can be augmented through pharmacoepidemiology research using data mining and data warehousing.
Introduction
Evidence-based medicine is strongly advocated by the U.S. National Institutes of Health [1] , and is a high funding priority. Between November 1992 and March 2006, 20,697 publications indexed by the National Library of Medicine list "evidence-based medicine" as a keyword (Figure 1 ). Evidence-based medicine is a structured analytical process in which published medical research is used to critically assess the efficacy and safety of different medical interventions. The objective of evidence-based medicine is to improve physician decision-making and patient outcomes while containing costs. Assessments begin with clear empirical definitions of the clinical question (end-point) to be evaluated. Exhaustive and structured literature search identifies published evidence that directly bears on the clinical question. Predefined rules are applied to assess quality of published evidence, and the extent to which it bears directly on the clinical question. The objective nature of evidence-based medicine can provide a powerful decision-support tool for practising physicians, and ultimately improve patient outcomes [3] . Limitations of evidence-based medicine include: (1) shortage of coherent, consistent scientific evidence, (2) difficulties in applying evidence to the care of individuals patients, (3) barriers to the practise of high quality medicine, (4) need for clinicians to develop new skills (literature search and synthesis), (5) clinicians have limited time and resources, and (6) misperception that clinical skills and expertise are denigrated by evidence-driven practise [3] . Data mining in pharmacoepidemiologic research can (1) overcome evidence shortages, (2) help provide information applicable to individuals patients, (3) support best practises in medicine, (4) provide summary sources to minimize the need to learn new computer skills, or (5) invest time and resources, and (6) be an adjunct to clinical expertise, not a replacement.
Wide interest in evidence-based medicine exists. Unfortunately, empirical data to support evidence-based decisions in medicine are not widely available. For example, comprehensive evaluation of evidence-based maternal dose formulation in obstetrics found that only one drug was adequately studied to guide clinical practice [4] . In such situations, a void in medical evidence exists, and clinical expertise is the only guide for practise. The lack of information in certain areas is an opportunity for advancement of the use of technology to improve medical practise and benefit the human condition [3] .
The objective of this paper is to demonstrate a general approach for the use of data warehousing, data mining, and pharmacoepidemiology technologies to advance evidence-based medicine. The aim of this demonstration project is to assess the gastrointestinal (GI) safety of etodolac, a generically available COX-2 selective analgesic. Patented COX-2 analgesics were removed from the US market because of an increased risk of acute myocardial infarction and stroke.
Materials and methods
The present investigation was approved by the Institutional Review Board for Use of Human Subjects, Veterans Affairs Medical Centre, Dallas, Texas, USA. Schema of data warehouse architecture.
Study subjects
The study subjects were U.S. Veterans who received health care and were prescribed naproxen or etodolac at the Veterans Affairs Medical Centre, Dallas, Texas, USA. Data were extracted from four separate databases that contain more than 294,000 unique patients. 
Data warehouse architecture
The analytical data warehouse was constructed by standardizing and joining four very large transactional databases. SAS and SAS Warehouse were integrated used for joining and administering the databases used in this study ( Figure 2 ).
Inclusion criteria
Figure 3: Inclusion criteria [5] . 
Analytical techniques
The endpoint of the analyses was whether or not study subjects had a bleeding ulcer or other GI event whilst taking one of the study medications. SAS (V.8.1) and SAS Enterprise Miner (V4.2) were used for the computations. PROC FREQ, PROC UNIVARIATE, and PROC LOGISTIC (Direct and Stepwise) were used in the analysis.
Results

Baseline patient characteristics
Patients in the study groups were similar, except etodolac patients were several years older than naproxen patients. Time to GI event (bleeding ulcer or other GI event, see Table 3 ) analysis revealed a wide separation between etodolac and naproxen within weeks of analgesic therapy (Figure 4 ). Etodolac  8601  4291  2098  1285  760  486  393  Naproxen  7735  3890  2176  1534  1065  783  692 Time to Event (Months) 0 2 4 6 8 10 12
Cumulative Incidence Rate (%) Naproxen Etodolac Figure 4 : Clinically significant upper GI events in patients not taking aspirin [5] .
The rates of upper GI events were significantly lower among patients treated with etodolac compared to naproxen ( Figure 5A ). Concomitant aspirin use caused the difference between etodolac and naproxen to disappear ( Figure 5B ).
Figure 5:
Rates of clinically significant upper GI events (number of events / patients years) [5] .
The rate of GI events per patient-year (pt-yrs) was higher among naproxenthan etodolac-exposed patients, and the most frequent site was upper GI. Table 3 :
Clinically significant upper GI events [5] .
Clinically significant Etodolac Naproxen Upper GI Event (2600 pt-yrs) (2996 pt-yrs) Symptomatic Gastroduodenal Ulcer 6 9 Upper GI Bleeding* 7 17 Perforation 0 2 Total 13 28 *The cause or source of upper GI bleeding was gastric ulcer in 7 patients, duodenal ulcers in 13, and other GI sources in 4 patients.
Aspirin is shown to alter the safety profile of etodolac, making it just as likely to be associated with a GI event as naproxen (Table 4) . 
Discussion
Collectively, in the absence of aspirin, these data indicate that a generic COX-2 agent is not associated with GI events when not used concomitantly with aspirin [5] , and may be a safe substitute for rofecoxib and celecoxib, pending publication of our ongoing analysis of the association between the generic drug and acute myocardial infarction. Using data warehouse and data mining technology with pharmacoepidemiology research, disparate data sources can remedy the shortage of coherent, consistent scientific evidence (see [3] ). Massive amounts of data remain not analyzed because they are not in a common format and reside in stovepipe databases. Evidence-based medicine can be advanced through the use of data warehouse architecture, data mining analysis, and pharmaco-epidemiology.
